Sales and Marketing

Showing 15 posts of 11526 posts found.

UN says Treatment 2.0 approach needed for AIDS

November 25, 2010 Research and Development, Sales and Marketing AIDS, HIV, UN, UNAIDS

A new report on the spread of AIDS has called for the development of new pharma compounds that will lead …
Tarceva tablet

Roche set to challenge NICE Tarceva decision

November 25, 2010 Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer

NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …

The renal cell carcinoma market: Votrient to challenge Sutent’s lead

November 25, 2010 Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma

After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …
Dr Reddy's Hyderabad, India

GSK sells antibiotics assets to Dr Reddy’s

November 24, 2010 Manufacturing and Production, Sales and Marketing Antibiotics, Dr Reddy's, GSK

Dr. Reddy’s Laboratories has bought a US oral penicillin facility from GSK, along with the US marketing rights to the …

Brain cancer vaccine to move into phase III

November 24, 2010 Research and Development, Sales and Marketing Celldex, Pfizer, brain cancer, glioblastoma

Celldex will press ahead with large-scale trials of its vaccine treatment for brain cancer after encouraging phase II results. The …

NICE recommends Herceptin for gastric cancer, blocks high dose Glivec

November 24, 2010 Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer

NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …
brinsmeadweb

Brinsmead to be life sciences adviser to government

November 23, 2010 Sales and Marketing Brinsmead, NHS, government, life sciences

Chris Brinsmead, chairman of AstraZeneca UK, has been made the government’s life sciences business adviser. He was appointed by universities …

Roche to develop diagnostic tools for Tarceva

November 23, 2010 Sales and Marketing Genzyme, NSCLC, Roche, Tarceva, diagnostic

Roche has obtained a worldwide sub-license from Genzyme to develop a diagnostic kit for the detection of specific mutations for …

Vytorin cuts heart problems in kidney patients

November 23, 2010 Sales and Marketing Merck, Vytorin, cardiovascular, simvastatin

Vytorin has been shown to reduce potentially heart problems in patients with chronic kidney disease (CKD) in a new study. …

Offshore outsourcing in Regulatory Affairs and Pharmacovigilance

November 22, 2010 Sales and Marketing Kinapse, White paper

Based on Kinapse’s direct experience, we explore the emerging environment for regulatory and pharmacovigilance offshore outsourcing within the biopharmaceutical industry …

A new generation of analogues for valuing strategy

November 22, 2010 Sales and Marketing Alex Blyth, MSI, forecasting, marketing, marketing strategy

Anyone who is involved in the planning of pharma marketing campaigns will know that the Holy Grail is trying to …
synovate_chris_king

Chris King joins Synovate Healthcare

November 22, 2010 Sales and Marketing Chris King, Synovate Healthcare, appointment, sales and marketing

Synovate has appointed Chris King head of its European Oncology Monitor within its specialist healthcare research division. He joins the …
Age-related macular degeneration (Wet AMD)

Bayer’s challenger to Lucentis shows promise

November 22, 2010 Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD

Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …

Daiichi-Sankyo cleared of rep misconduct

November 22, 2010 Medical Communications, Sales and Marketing ABPI, ABPI Code of Practice, Daiichi Sankyo, Daiichi-Sankyo, Olmetec, PMCPA, olmesartan, pharma sales representative

Daiichi-Sankyo has been cleared of any wrongdoing in relation to the ABPI Code after one of its representatives was accused …

Pfizer’s axitinib impresses in head-to-head trial with Nexavar

November 22, 2010 Research and Development, Sales and Marketing Kidney cancer, Nexavar, Pfizer, axitinib, mRCC, metastatic renal cell carcinoma

Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …
The Gateway to Local Adoption Series

Latest content